Analyses of drug-treated samples revealed increased intratumor recruitment of activated cytotoxic T cells and natural killers, concomitant with the downregulation of forkhead box protein P3 (Foxp3)<sup>+</sup> T-cell surface glycoprotein CD4 (CD4)<sup>+</sup> T cells, indicating that carfilzomib promotes reshaping of the immune microenvironment of BRAF-mutant murine colorectal tumors. This evidence concerns the gene CD4 and colorectal neoplasm.